Oncopeptides in brief

Oncopeptides in brief

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient quality of life.

Oncopeptides uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Commercial launch

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The product is currently not marketed in the US, due to regulatory hurdles. Oncopeptides has an ongoing dialogue with the FDA regarding the regulatory path forward. 

Proprietary technology platforms

Oncopeptides is developing several new compounds based on the proprietary technology platforms, Peptide Drug Conjugate (PDC) and Small Polypeptide based Killer Engagers (SPiKE).

Listing and location

Oncopeptides AB (publ) is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

The headquarters is in Stockholm, Sweden, and a modern pre-clinical drug development facility in Solna, outside Stockholm, Sweden.

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more


Following the recent withdrawal of Pepaxto in the US, Oncopeptides has taken significant measures to refocus the company on R&D, reduce the clinical development program, close the commercial business units in the US and EU, and downsize the organization to increase the cash runway and build a platform for longer term development and growth. The company has also...

Read more

Governance structure

Oncopeptides’ corporate governance has, prior to the listing on Nasdaq Stockholm, been governed by the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)), the Swedish Annual Accounts Act (Sw. årsredovisningslagen (1995:1554)) and other applicable laws and regulations, the Company’s articles of association and internal policy documents.

Read more